Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.
You may also be interested in...
AbbVie Sets Out To Win Over Investors In Its First Financial Call
Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.
Abbott, BMS Suffer Blows On Antiretrovirals Kaletra and Reyataz As Indian Patent Office Rejects Patent Claims
MUMBAI - India's Deputy Controller of Patents and Designs from the Mumbai branch of the Indian Patent Office rejected Dec. 30 Abbott's patent request for its popular second-generation antiretroviral Kaletra (lopinavir/ritonavir). Abbott had applied for a patent of a heat stable formulation of Kaletra nearly three years ago
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.